Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Catalent Inc.
Headquarters: Somerset, NJ, United States of America
Website: http://www.catalent.com
Year Founded: 2007
Status: Private
Industry Sector: N/A
CEO: N/A
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: N/A
Exchange/Ticker 1: N/A
Exchange/Ticker 2: N/A
Latest Market Cap: N/A
BioCentury | May 14, 2024
Deals
Deals Report: Sanofi-Novavax to co-commercialize Nuvaxovid, develop combination vaccines
Plus: Maze finds Pompe disease program partner in Shionogi, and updates from Takeda-AC Immune, Sanofi-Fulcrum and more
BioCentury | Feb 16, 2024
Finance
Venture report: Earlybird’s €173M fund, launches for Firefly and Latigo
European VC closes new vehicle; start-ups backed by Versant, Westlake Village out of stealth; Medicxi’s bundle; rounds for Freenome, ProfoundBio
BioCentury | Feb 6, 2024
Deals
Deals roundup: Novo boosts obesity manufacturing with Catalent buy
BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5
BioCentury | Sep 20, 2023
Management Tracks
Orwin succeeds Topper as AnaptysBio’s chair
Plus: CDMOs Catalent and Rentschler announce executive changes, and updates from Parexel, Santander, CorriXR and more
BioCentury | Sep 18, 2023
Product Development
Bertozzi’s click chemistry could be key for allogeneic cell therapies
2022 Nobel Prize winner Bertozzi joins Acepodia as chief scientific adviser
BioCentury | Jan 4, 2023
Management Tracks
Ex-Checkmate CEO Bash to lead ZielBio
Plus: Allogene’s Amado joins Zai Lab, and updates from bluebird bio, Rejuvenate, Novadip and more
BioCentury | Nov 8, 2022
Emerging Company Profile
Lusaris: treating depression with a new version of an old psychotropic
RA Capital leads $60M series A for the company, which is using Catalent’s technology to deliver 5-MeO-DMT
BioCentury | Oct 6, 2022
Data Byte
Companies founded by Nobel Prize winner Bertozzi
The eighth female to win the Nobel in chemistry has founded at least eight companies
BioCentury | Jul 6, 2022
Deals
July 5 Quick Takes: Details of Pfizer-Biohaven negotiations emerge
Plus second adcomm for Amylyx’s ALS therapy, female biotech leaders criticize SCOTUS decision, and updates from Juvisé, Syros and more
BioCentury | Jul 5, 2022
Management Tracks
Health Secretary Javid among ministers quitting U.K. government
Plus Hering made permanent CEO at Adagio and updates from Canbridge, Catalent, Nanoscope, and more
Items per page:
1 - 10 of 64